Tuesday, January 6, 2026, yielded two surprising updates from the Food and Drug Administration (“FDA”) Center for Devices and Radiological Health. While many experts have been forecasting continued ...
The pharmaceutical industry is experiencing its own “DeepSeek moment,” according to science writer Hiya Jain. Just as the upstart AI breakthrough caught Silicon Valley off-guard, China is emerging as ...
-- Proceeds to drive global Phase 3 trial for ASP-1929, targeting BLA submission to the U.S. FDA in 2028 -- Financing led by international life science fund TaiAx, with participation from the largest ...
Opinions expressed by Digital Journal contributors are their own. Bringing a new biologic drug from concept to clinic is a complex journey fraught with technical and regulatory hurdles. For ...
The FDA has qualified its first artificial intelligence tool to help drug developers evaluate fatty liver disease in their clinical trials. The agency gave a green light to the AI-Based Histologic ...
Forbes contributors publish independent expert analyses and insights. Gil Press writes about technology, entrepreneurs and innovation. Will AI transform the typical trials and tribulations of drug ...
CellVoyant, an AI-first biotech based in Bristol UK, today launches FateView™, the first online predictive cell analytics platform designed to help cell-based therapeutic drug developers reduce costs ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback